|

Ultra-Rapid Profiling and Drug Screening for Treatment Selection in Patients With Relapsed or Recurrent Rare Brain Tumors

RECRUITINGN/ASponsored by Adriana Fonseca
Actively Recruiting
PhaseN/A
SponsorAdriana Fonseca
Started2026-10
Est. completion2032-01
Eligibility
Healthy vol.Accepted
Locations1 site

Summary

The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in of performing real-time drug screening on tissue taken during surgery in patients with relapsed ultra rare brain tumors (BCOR -altered, MN1-altered, CNS Sarcomas, other rare brain tumors) and of having a specialized tumor board assign a treatment plan based on the results of the drug screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed ultra rare brain tumors to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

1. Patients must have a relapse or recurrence of one of the following rare brain tumors:

   * CNS sarcoma (e.g. EWS, CIC, DICER1 altered)
   * BCOR altered tumors (e.g. BCOR ITD; BCOR, BCORL1, EP300, fused)
   * Mesenchymal tumors (e.g. FET::CREB altered tumors)
   * MN1::PATZ1 fused tumors
   * PLAG- altered tumors
   * Astroblastomas/MN-1 altered (e.g. EWSR2BEND2 altered)
   * Unclassifiable tumors
   * Other rare brain tumors: (e.g. recently described, poorly characterized, and/or ambiguous entities)
2. Participant must be a candidate for surgical resection or biopsy.

   • Participants must have surgically accessible disease.
3. Prior therapy

   • The participant must have a relapsed or recurrent rare brain tumor following at least one prior therapy for initial diagnosis or previous recurrence prior to study registration:
   * Surgery followed by observation.
   * Multi-modality therapy: surgery, radiation, and/or chemotherapy
4. Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

   * Biologic agent: Participant must have recovered from any toxicity potentially related to the agent.
   * Last radiation at least 7 days prior to therapy start
5. Karnofsky 50 for participants \> 16 years of age and Lansky 50 for participants \<16 years of age
6. Corticosteroids: Subjects who are receiving dexamethasone or equivalent must be on a stable or decreasing dose for at least 1 week prior to therapy start.
7. The effects of the agents used in this study on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 4 months after completion of therapy administration.
8. Adequate neurologic function defined as:

   • Participants with seizure disorders may be enrolled if seizures are well controlled. Participants on non-enzyme inducing anticonvulsants may be excluded pending interaction(s) with study drug.
9. A legal parent or guardian must be able to understand and agree to sign a written informed consent and assent document, as appropriate.

Exclusion Criteria:

1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection.
2. Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required prior to start of therapy.

Conditions7

BCOR ITD SarcomaCNS SarcomaCancerFOXR2-activatedMesenchymal TumorPLAG-altered TumorsRare CNS Tumor

Locations1 site

Children's National Hospital
Washington D.C., District of Columbia, 20010

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.